What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?

dc.contributor.authorBakırcı, Sibel
dc.contributor.authorSolmaz, Dilek
dc.contributor.authorAl Osaimi, Noura
dc.contributor.authorCan, Meryem
dc.contributor.authorErden, Abdulsamed
dc.contributor.authorÖzişler, C.
dc.contributor.authorÇınar, Muhammet
dc.contributor.authorKılıç, Levent
dc.contributor.authorKüçük, A.
dc.contributor.authorOmma, Ahmet
dc.contributor.authorYıldız, Fatih
dc.contributor.authorDoğru, Atalay
dc.contributor.authorEsmen, Serpil Ergülü
dc.contributor.authorAkar, Servet
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorAydın, Sibel Zehra
dc.contributor.authorTufan, Abdurrahman
dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.tr_TR
dc.contributor.researcheridCMF-4757-2022
dc.contributor.scopusid6506739457
dc.date.accessioned2024-02-06T12:18:25Z
dc.date.available2024-02-06T12:18:25Z
dc.date.issued2019-09
dc.description.abstractObjective: Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO). The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA(+) or MDA(-)).MethodsPsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry. PsA patients who had at least 1 year of disease duration and had full data for MDA were included for this analysis (n=317). Patients were considered in MDA+ when they met at least 5/7 of the MDA criteria.ResultsMDA was achieved in 46% patients. Within MDA- patients, body surface area (51.2%) and swollen joint count (53.5%) domains could still be achieved in the majority and 93.5% of them had no enthesitis using the Leeds enthesitis index. Of 170 patients with MDA-, 90 patients did not fulfill all 3 PROs of MDA. Mono-arthritis subtype (RR: 2.01), absence of enthesitis (RR: 1.570) and absence of distal interphalangeal (DIP) joint disease (RR: 1.1) were associated with higher probability of achieving MDA.ConclusionThe MDA criteria provide an objective target for treatment in trials and clinical practice; however, in real life PROs are the most significant barriers to achieve MDA. The presence of DIP joints disease makes it difficult to reach MDA due to active PROs.en_US
dc.description.sponsorshipTürk Romatoloji Derneği (TRD)tr_TR
dc.description.sponsorshipUnion Chimique Belge (UCB)en_US
dc.identifier.citationBakırcı, S. vd. (2019). "What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?". Clinical and Experimental Rheumatology, 37(5), 808-812.en_US
dc.identifier.eissn1593-098X
dc.identifier.endpage812tr_TR
dc.identifier.issn0392-856X
dc.identifier.issue5tr_TR
dc.identifier.pubmed30767863tr_TR
dc.identifier.scopus2-s2.0-85072349561
dc.identifier.startpage808tr_TR
dc.identifier.urihttps://europepmc.org/article/med/30767863
dc.identifier.urihttps://hdl.handle.net/11452/39565
dc.identifier.volume35tr_TR
dc.identifier.wos000485817300014
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalClinical & Exper Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.relation.tubitakTÜBİTAKtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPsoriatic arthritisen_US
dc.subjectMinimal disease activityen_US
dc.subjectPatient-reported outcomesen_US
dc.subjectPredictorsen_US
dc.subjectCriteriaen_US
dc.subjectRheumatologyen_US
dc.subjectPsoriasisen_US
dc.subject.emtreeAntirheumatic agenten_US
dc.subject.emtreeBiological producten_US
dc.subject.emtreeDisease exacerbationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreePsoriatic arthritisen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeSeverity of illness indexen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.meshAntirheumatic agentsen_US
dc.subject.meshArthritis, psoriaticen_US
dc.subject.meshBiological productsen_US
dc.subject.meshDisease progressionen_US
dc.subject.meshHumansen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshRemission inductionen_US
dc.subject.meshSeverity of illness indexen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusPustulosis Palmoplantaris; Secukinumab; Nail Diseasesen_US
dc.subject.wosRheumatologyen_US
dc.titleWhat are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?en_US
dc.typeArticleen_US
dc.wos.quartileQ2 (Rheumatology)en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections